Drug intelligence / Profile preview

MVX #205

Development stage: Preclinical
Lead developer: MalarVx
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MVX #205 is a self-amplifying replicon RNA (repRNA) vaccine candidate being developed by MalarVx, in collaboration with HDT Bio, for the prevention of malaria. The vaccine utilizes HDT Bio's proprietary Lipid InOrganic Nanocarrier (LION) formulation to deliver repRNA encoding the circumsporozoite protein (CSP) of Plasmodium falciparum. This platform is designed to enhance vaccine stability, simplify manufacturing, and elicit robust humoral and cellular immune responses, including liver-resident memory CD8+ T cells, to provide long-lasting protection against malaria. MVX #205 is currently in IND-enabling development.

Targets

CSP (Circumsporozoite protein)PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on MVX #205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVX #205.

Explore the full profile